Biological regulatory networks are less nonlinear than expected by chance

Nonlinearity is a characteristic of complex biological regulatory networks that has implications ranging from therapy to control. To better understand its nature, we analyzed a suite of published Boolean network models, containing a variety of complex nonlinear interactions, with an approach involving a probabilistic generalization of Boolean logic that George Boole himself had proposed. Leveraging the continuous-nature of this formulation using Taylor-decomposition methods revealed the distinct layers of nonlinearity of the models. A comparison of the resulting series of model approximations with the corresponding sets of randomized ensembles furthermore revealed that the biological networks are relatively more linearly approximable. We hypothesize that this is a result of optimization by natural selection for the purpose of controllability.

Drug target ranking for glioblastoma multiforme

Background Glioblastoma Multiforme, an aggressive primary brain tumor, has a poor prognosis and no effective standard of care treatments. Most patients undergoing radiotherapy, along with Temozolomide chemotherapy, develop resistance to the drug, and recurrence of the tumor is a common issue after the treatment. We propose to model the pathways active in Glioblastoma using Boolean network techniques. The network captures the genetic interactions and possible mutations that are involved in the development of the brain tumor. The model is used to predict the theoretical efficacies of drugs for the treatment of cancer. Results We use the Boolean network to rank the critical intervention points in the pathway to predict an effective therapeutic strategy for Glioblastoma. Drug repurposing helps to identify non-cancer drugs that could be effective in cancer treatment. We predict the effectiveness of drug combinations of anti-cancer and non-cancer drugs for Glioblastoma. Conclusions Given the genetic profile of a GBM tumor, the Boolean model can predict the most effective targets for treatment. We also identified two-drug combinations that could be more effective in killing GBM cells than conventional chemotherapeutic agents. The non-cancer drug Aspirin could potentially increase the cytotoxicity of TMZ in GBM patients.